Key Drivers
- Liquidity Cushion
- Debt Burden
- Weak Cash Flow
AIAI Summary
ESPR should now be viewed as a deal-driven special situation rather than a standalone turnaround, with the ARCHIMED $3.16 cash take-private plus contingent rights capping upside and making the key question whether the transaction closes cleanly amid shareholder process scrutiny and a fragile, leverage-heavy balance sheet.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Cushion
- •Debt Burden
- •Weak Cash Flow
ESPR has solid gross margins and enough near-term liquidity, but heavy debt, negative equity, and persistent negative cash flow keep financial risk elevated.
ക
Price Behavior
Key Price Behavior Insights:
- •Breakout hold
- •Tight consolidation
- •Pullback risk
ESPR broke above $3.00 over the last month, held $3.11-$3.15 as support, and remains constructive but short-term stretched until it clears $3.15.
Sharp repricing from the ~$2.00 base to above $3.00 in one step
Sentiment & News
Key News Insights:
- •Buyout premium
- •Legal scrutiny
- •Pipeline updates
Esperion's stock surged after ARCHIMED agreed to take the company private for up to $1.1B, but shareholder lawsuits and fairness reviews are adding deal risk. #M&A
The acquisition is the main catalyst, but ongoing legal and process concerns may cap upside until the deal closes
Similar Companies in Healthcare
Other companies in the same sector with AI ratings